RHEACELL GmbH & Co. KG

TICEBA founds subsidiary RHEACELL.

TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 01TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 02

RHEACELL is dedicated to the development of pharmaceuticals based on ABCB5-positive (ABCB5+) mesenchymal stem cells as a platform technology. An integral part of RHEACELL's research program is the development of novel and innovative therapeutic approaches and their review in clinical trials. In the end, patients should be offered new treatment options for diseases that have not been or are insufficiently treatable.

TICEBA contributes its established know-how as well as its qualified employees to the success of the development of pharmaceuticals of RHEACELL. TICEBA produces high quality stem cells as a drug (§13 AMG) for the clinical trials conducted by RHEACELL.

Please click HERE for more information on RHEACELL.

TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 03

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter